GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study

NCT07457281 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma HNSCC

Interventions

DRUG: GV20-0251
DRUG: Sintilimab

Sponsor

West China Hospital